These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9007954)

  • 1. A survey of heparin monitoring in Australasia.
    Mackinlay N; Favaloro E; Arthur C; Smith J; Aboud M
    Pathology; 1996 Nov; 28(4):343-7. PubMed ID: 9007954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin.
    Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Lloyd J; Street A; Marsden K;
    Pathology; 2005 Jun; 37(3):234-8. PubMed ID: 16175898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges.
    van den Besselaar AM; Sturk A; Reijnierse GL
    Thromb Res; 2002 Sep; 107(5):235-40. PubMed ID: 12479884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range.
    Marlar RA; Gausman JN
    Int J Lab Hematol; 2012 Dec; 34(6):614-20. PubMed ID: 22712447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience.
    Becker RC; Cyr J; Corrao JM; Ball SP
    Am Heart J; 1994 Oct; 128(4):719-23. PubMed ID: 7942443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current considerations in the use of the APTT in monitoring unfractionated heparin.
    Nelson DE
    Clin Lab Sci; 1999; 12(6):359-64. PubMed ID: 10724634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin monitoring in Australasia: survey of laboratory practices in 2000.
    Morris RG; Lam AK
    Ther Drug Monit; 2002 Aug; 24(4):471-8. PubMed ID: 12142629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
    Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of aPTT reporting in Canadian medical laboratories. The need for increased standardization. Thrombosis Interest Group of Canada.
    Brigden ML; Johnston M
    Am J Clin Pathol; 2000 Aug; 114(2):276-82. PubMed ID: 10941344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.
    Simko RJ; Tsung FF; Stanek EJ
    Ann Pharmacother; 1995 Oct; 29(10):1015-21; quiz 1061. PubMed ID: 8845539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
    Baluwala I; Favaloro EJ; Pasalic L
    Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.